TAT-PDCD4 (programmed cell death 4) fusion protein and application of TAT-PDCD4 fusion protein in drug for treating ovarian cancer

A fusion protein, the technology in the sequence listing, applied in the biological field to achieve the effects of inhibiting proliferation and migration, no toxic side effects, and high transmembrane rate

Inactive Publication Date: 2018-09-28
SHANDONG UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, the combination of TAT and PDCD4 has not been applied to the preparation of drugs for the treatment of ovarian cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TAT-PDCD4 (programmed cell death 4) fusion protein and application of TAT-PDCD4 fusion protein in drug for treating ovarian cancer
  • TAT-PDCD4 (programmed cell death 4) fusion protein and application of TAT-PDCD4 fusion protein in drug for treating ovarian cancer
  • TAT-PDCD4 (programmed cell death 4) fusion protein and application of TAT-PDCD4 fusion protein in drug for treating ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Embodiment 1 Construction of TAT-PDCD4-His recombinant expression vector

[0041] Construction of the fusion gene: design primers according to the DNA sequence of SEQ ID No.5 (see Table 1 below), fuse the gene sequence by primer synthesis PCR method, and clone it into the expression vector pET30a(+).

[0042] Table 1 Primers

[0043]

[0044] 1. Obtain the cloned target sequence by PCR:

[0045] a. Full-length PCR: see Table 2 for the reaction system:

[0046] Table 2 One round reaction system of full-length PCR reaction system

[0047]

[0048] Reaction condition: 95°C for 3min

[0049]

[0050] b. Recover the PCR product of the above steps by glue: the above product is recovered by tapping the rubber.

[0051] c.Gibson recombination reaction experiment

[0052] 1) Simultaneously with PCR, the pET30a(+) plasmid was treated with NdeI / BamHI for gel recovery.

[0053] 2) Gibson recombination reaction system: Add 5 ul of the above-mentioned PCR recovery prod...

Embodiment 2

[0056] Induced expression and purification of embodiment 2 TAT-PDCD4-His fusion protein in Escherichia coli

[0057] Transform the recombinant cloning plasmid with correct sequencing into Escherichia coli BL21 (DE3) competent cells, pick a single clone colony and inoculate it into 2ml PBL medium (containing kanamycin) for overnight culture on a shaker. The next day, inoculate into large-volume LB medium at a ratio of 1:100, culture at 250 rpm until the OD 600 is between 0.3-0.5, then add an appropriate amount of inducer IPTG, continue to culture on a shaker for 6 hours, and centrifuge to discard the supernatant for later use. cassette for protein purification and endotoxin removal. Then carry out SDS-PAGE and Western-blot analysis to it, such as figure 1 , Judging from the molecular weight, the protein obtained in lane 1 is a TAT-PDCD4 fusion protein. Therefore, the TAT-PDCD4-His fusion protein was successfully expressed and purified in this experiment.

Embodiment 3

[0058] Example 3 Study on the transmembrane velocity of TAT-PDCD4-HIS

[0059] 1) Inoculation of cells Ovarian cancer cell-SKOV3 was digested with trypsin, counted, and then inoculated into 24-well cell culture plates with coverslips placed in advance. Incubate overnight at 37°C, 5% CO2.

[0060] 2) Fusion protein TAT-PDCD4 stimulates the cells to discard the supernatant, add TAT-PDCD4 protein containing 5ug / ml, and continue culturing for 30 minutes, 1 hour and 3 hours respectively.

[0061] 3) Fix with 4% paraformaldehyde for 10 minutes before staining antibody treatment (300ul per well), then incubate with mouse anti-human PDCD4 antibody for 1 hour, then treat with FITC-rabbit anti-mouse secondary antibody for 30 minutes, and then treat cells with DAPI 3 Minutes, finally take out the coverslip, place the cells on the slide with the cells facing down, add an appropriate amount of anti-fade agent, and seal the slide for later use.

[0062] 4) Laser confocal microscope observ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a TAT-PDCD4 (programmed cell death 4) fusion protein and the application of the TAT-PDCD4 fusion protein in a drug for treating an ovarian cancer. The TAT-PDCD4 fusion protein comprises a core peptide fragment region of TAT, PDCD4 and a His tag. The fusion protein is high in transmembrane velocity, can efficiently carry the PDCD4 and target to ovarian cancer cells, is high in inhibition capacity for multiplication and migration of the ovarian cancer and can take effect for a long time in vivo. The TAT-PDCD4 fusion protein provided by the invention can be used as a drug,which is relatively low in toxicity to non-targeted tissues or cells, and the safety is guaranteed; a new way or idea is provided for treatment of ovarian cancer diseases. By in-vitro expression of the TAT-PDCD4 fusion protein, the TAT-PDCD4 fusion protein is high in expression volume, high in controllability and relatively low in production cost, and large-scale production is easy to realize.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a TAT-PDCD4 fusion protein and its application in drugs for treating ovarian cancer. Background technique [0002] Ovarian cancer is one of the three common malignant tumors of the female reproductive system, and the mortality rate of ovarian epithelial cancer ranks first among gynecological tumors. The onset of the tumor is hidden, the early symptoms are not obvious, and it is difficult to find. When the diagnosis is made, 60% to 70% of them are in the advanced stage, and most of them have spread to the bilateral appendages of the uterus, omentum and pelvic organs. It is difficult to remove the tumor by surgery. organize. Moreover, the effects of postoperative radiotherapy and chemotherapy are unsatisfactory, and it is urgent to find an adjuvant drug for postoperative adjuvant therapy to remove residual tumor cells or tissues. [0003] PDCD4 (programmed cell death 4) i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/70A61K38/08A61P35/00
CPCC07K14/005A61K38/00A61P35/00C07K14/82C07K2319/00C12N15/70C12N2740/16022
Inventor张利宁朱法良王群李艳郭春李媛王革
OwnerSHANDONG UNIV